INOVIO Pharmaceuticals
NEWS ALERT

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Press Releases

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Posted on July 9, 2025

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Posted on July 9, 2025

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

Posted on July 9, 2025

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Posted on July 9, 2025

INOVIO to Present at Upcoming Scientific Conferences

Posted on July 9, 2025

INOVIO to Present at Upcoming Scientific Conference

Posted on July 7, 2025

INOVIO to Present at Upcoming Scientific Conference

Posted on July 7, 2025

INOVIO Announces Pricing of $25 Million Public Offering

Posted on July 3, 2025

INOVIO Announces Pricing of $25 Million Public Offering

Posted on July 3, 2025

INOVIO Announces Proposed Public Offering

Posted on July 2, 2025

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.